Bacher, Ulrike

[["dc.bibliographiccitation.firstpage","146"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Acta Haematologica"],["dc.bibliographiccitation.lastpage","154"],["dc.bibliographiccitation.volume","134"],["dc.contributor.author","Mendorf, Alexander"],["dc.contributor.author","Klyuchnikov, Evgeny"],["dc.contributor.author","Langebrake, Claudia"],["dc.contributor.author","Rohde, Holger"],["dc.contributor.author","Ayuk, Francis"],["dc.contributor.author","Regier, Marc"],["dc.contributor.author","Christopeit, Maximilian"],["dc.contributor.author","Zabelina, Tatjana"],["dc.contributor.author","Bacher, Adelbert"],["dc.contributor.author","Wolschke, Christine"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Stübig, Thomas"],["dc.date.accessioned","2018-11-07T10:02:55Z"],["dc.date.available","2018-11-07T10:02:55Z"],["dc.date.issued","2015"],["dc.description.abstract","Toxoplasmosis and infections by other opportunistic agents such as Pneumocystis jirovecii constitute life-threatening risks for patients after allogeneic hematopoietic stem cell transplantation. Trimethoprim/sulfamethoxazole (TMP-SMX) has been well established for post-transplant toxoplasmosis and pneumocystis prophylaxis, but treatment may be limited due to toxicity. We explored atovaquone as an alternative and compared it with TMP-SMX regarding toxicity and efficacy during the first 100 days after transplantation in 155 consecutive adult stem cell recipients. Eight patients with a prior history of TMP-SMX intolerance received atovaquone as first-line prophylaxis. TMP-SMX was used for 141 patients as first-line strategy, but 13 patients (9.2%) were later switched to atovaquone due to TMP-SMX toxicity or gastrointestinal symptoms. No active toxoplasmosis or active P. jirovecii infection developed under continued prophylaxis with either TMP-SMX or atovaquone. However, for reasons of TMP-SMX and/or atovaquone toxicity, 7 patients were unable to tolerate any efficacious toxoplasmosis prophylaxis and therefore obtained inhalative pentamidine as P. jirovecii prophylaxis but no toxoplasmosis prophylaxis. Importantly, 2 of these patients developed severe toxoplasmosis. In summary, atovaquone appears as a valid alternative for at least some post-transplant patients who cannot tolerate TMP-SMX. This should be further confirmed by multicenter trials. (C) 2015 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000380757"],["dc.identifier.isi","000361636000003"],["dc.identifier.pmid","25968483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38332"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9662"],["dc.relation.issn","1421-9662"],["dc.relation.issn","0001-5792"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","766"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Current Oncology"],["dc.bibliographiccitation.lastpage","776"],["dc.bibliographiccitation.volume","29"],["dc.contributor.affiliation","Shumilov, Evgenii; 1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; Evgenii.Shumilov@ukmuenster.de (E.S.); Myriam.Legros@insel.ch (M.L.); NaomiAzur.Porret@insel.ch (N.P.)"],["dc.contributor.affiliation","Mazzeo, Paolo; 3Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37075 Göttingen, Germany; paolo.Mazzeo@med.uni-goettingen.de (P.M.); detlef.haase@med.uni-goettingen.de (D.H.)"],["dc.contributor.affiliation","Zinkernagel, Martin S.; 4Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; martin.zinkernagel@insel.ch"],["dc.contributor.affiliation","Legros, Myriam; 1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; Evgenii.Shumilov@ukmuenster.de (E.S.); Myriam.Legros@insel.ch (M.L.); NaomiAzur.Porret@insel.ch (N.P.)"],["dc.contributor.affiliation","Porret, Naomi; 1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; Evgenii.Shumilov@ukmuenster.de (E.S.); Myriam.Legros@insel.ch (M.L.); NaomiAzur.Porret@insel.ch (N.P.)"],["dc.contributor.affiliation","Romagna, Lorenz; 5Department of Medical Oncology, Inselspital, Bern University Hospital, 3012 Bern, Switzerland; lorenz.romagna@insel.ch (L.R.); Urban.Novak@insel.ch (U.N.); Thomas.Pabst@insel.ch (T.P.)"],["dc.contributor.affiliation","Haase, Detlef; 3Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37075 Göttingen, Germany; paolo.Mazzeo@med.uni-goettingen.de (P.M.); detlef.haase@med.uni-goettingen.de (D.H.)"],["dc.contributor.affiliation","Lenz, Georg; 2Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, 48149 Münster, Germany; Georg.Lenz@ukmuenster.de"],["dc.contributor.affiliation","Novak, Urban; 5Department of Medical Oncology, Inselspital, Bern University Hospital, 3012 Bern, Switzerland; lorenz.romagna@insel.ch (L.R.); Urban.Novak@insel.ch (U.N.); Thomas.Pabst@insel.ch (T.P.)"],["dc.contributor.affiliation","Banz, Yara; 6Institute of Pathology, University of Bern, 3012 Bern, Switzerland; yara.banz@pathology.unibe.ch"],["dc.contributor.affiliation","Pabst, Thomas; 5Department of Medical Oncology, Inselspital, Bern University Hospital, 3012 Bern, Switzerland; lorenz.romagna@insel.ch (L.R.); Urban.Novak@insel.ch (U.N.); Thomas.Pabst@insel.ch (T.P.)"],["dc.contributor.affiliation","Bacher, Ulrike; 1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, Switzerland; Evgenii.Shumilov@ukmuenster.de (E.S.); Myriam.Legros@insel.ch (M.L.); NaomiAzur.Porret@insel.ch (N.P.)"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Mazzeo, Paolo"],["dc.contributor.author","Zinkernagel, Martin S."],["dc.contributor.author","Legros, Myriam"],["dc.contributor.author","Porret, Naomi"],["dc.contributor.author","Romagna, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Lenz, Georg"],["dc.contributor.author","Novak, Urban"],["dc.contributor.author","Banz, Yara"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Pabst, Thomas"],["dc.date.accessioned","2022-04-01T10:03:17Z"],["dc.date.available","2022-04-01T10:03:17Z"],["dc.date.issued","2022"],["dc.date.updated","2022-09-03T17:14:09Z"],["dc.description.abstract","Background: Intraocular lymphoma (IOL) presents a real challenge in daily diagnostics. Cyto- and/or histopathology of vitreous body represent the diagnostic cornerstones. Yet, false negative results remain common. Therefore, we analyzed the diagnostic significance of flow cytometry (FC) within the workup algorithm of IOL and compared its sensitivity with the results obtained from routine cytopathology and molecular genetics; Methods: Seven patients undergoing vitrectomy due to suspected IOL were investigated by FC and parallel cytopathology and, if available, digital droplet PCR (ddPCR) for MYD88 L265P; Results: Four out of seven patients were finally diagnosed with IOL. Among the IOL patients, cytopathology confirmed the presence of lymphoma cells in only two cases. In contrast, FC was positive for IOL in all four cases, and FC additionally confirmed the lack of IOL in the remaining patients. In IOL patients diagnosed by FC and with available ddPCR, the diagnosis of IOL was confirmed by the presence of the MYD88 L265P mutation in all three patients; Conclusions: The combination with FC was superior to cytopathology alone in the diagnostic work-up of IOL, and it showed an excellent correlation with ddPCR results. A comprehensive diagnostic panel consisting of cytopathology, FC and molecular genetics should be considered for the work-up of suspected IOL."],["dc.identifier.doi","10.3390/curroncol29020065"],["dc.identifier.pii","curroncol29020065"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/106131"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1718-7729"],["dc.rights","CC BY 4.0"],["dc.title","Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e2015034"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Mediterranean Journal of Hematology and Infectious Diseases"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2016-08-22T12:41:23Z"],["dc.date.accessioned","2021-10-27T13:20:38Z"],["dc.date.available","2016-08-22T12:41:23Z"],["dc.date.available","2021-10-27T13:20:38Z"],["dc.date.issued","2015"],["dc.description.abstract","The karyotype represents one of the main cornerstones for the International Prognostic Scoring System (IPSS) and the revised IPSS-R (IPSS-R) that are most widely used for prognostication in patients with myelodysplastic syndromes (MDS). The most frequent cytogenetic abnormalities in MDS, i.e. del(5q), -7/del(7q), +8, complex karyotypes, or -Y have been extensively explored for their prognostic impact. The IPSS-R also considers some less frequent abnormalities such as del(11q), isochromosome 17, +19, or 3q abnormalities. However, more than 600 different cytogenetic categories had been identified in a previous MDS study. This review aims to focus interest on selected rare cytogenetic abnormalities in patients with MDS. Examples are numerical gains of the chromosomes 11 (indicating rapid progression), of chromosome 14 or 14q (prognostically intermediate to favorable), -X (in females, with an intermediate prognosis), or numerical abnormalities of chromosome 21. Structural abnormalities are also considered, e.g. del(13q) that is associated with bone marrow failure syndromes and favorable response to immunosuppressive therapy. These and other rare cytogenetic abnormalities should be integrated into existing prognostication systems such as the IPSS-R. However, due to the very low number of cases, this is clearly dependent on international collaboration. Hopefully, this article will help to inaugurate this process."],["dc.identifier.doi","10.4084/MJHID.2015.034"],["dc.identifier.fs","618516"],["dc.identifier.pmid","25960862"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13585"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/91971"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.issn","2035-3006"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Rare cytogenetic abnormalities in myelodysplastic syndromes."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Blood Cancer Journal"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Cevik, Naciye"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2020-12-10T18:09:40Z"],["dc.date.available","2020-12-10T18:09:40Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1038/s41408-018-0061-z"],["dc.identifier.eissn","2044-5385"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15581"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73724"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Shumilov, Evgenii; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Aperdannier, Lena; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Schmidt, Nicole; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Szuszies, Christoph; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Neesse, Albrecht; 3Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; albrecht.neesse@med.uni-goettingen.de"],["dc.contributor.affiliation","Hoffknecht, Petra; 4Department of Thorax Oncology, Franziskus-Hospital Harderberg, Niels-Stensen-Kliniken, 49124 Georgsmarienhütte, Germany; petra.hoffknecht@niels-stensen-kliniken.de"],["dc.contributor.affiliation","Khandanpour, Cyrus; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Mikesch, Jan-Henrik; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Stelljes, Matthias; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Boeckel, Göran Ramin; 6Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany; goeranramin.boeckel@ukmuenster.de (G.R.B.); phil-robin.tepasse@ukmuenster.de (P.-R.T.)"],["dc.contributor.affiliation","Tepasse, Phil-Robin; 6Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany; goeranramin.boeckel@ukmuenster.de (G.R.B.); phil-robin.tepasse@ukmuenster.de (P.-R.T.)"],["dc.contributor.affiliation","Reitnauer, Lea; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Koch, Raphael; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Hasenkamp, Justin; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Bacher, Ulrike; 8Central Hematology Laboratory, Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; veraulrike.bacher@insel.ch"],["dc.contributor.affiliation","Scheithauer, Simone; 9Department of Infection Control and Infectious Diseases, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; simone.scheithauer@med.uni-goettingen.de"],["dc.contributor.affiliation","Trümper, Lorenz; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Schmitz, Norbert; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Wulf, Gerald; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Kerkhoff, Andrea; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Lenz, Georg; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Krekeler, Carolin; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Bleckmann, Annalen; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Aperdannier, Lena"],["dc.contributor.author","Schmidt, Nicole"],["dc.contributor.author","Szuszies, Christoph"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Hoffknecht, Petra"],["dc.contributor.author","Khandanpour, Cyrus"],["dc.contributor.author","Mikesch, Jan-Henrik"],["dc.contributor.author","Stelljes, Matthias"],["dc.contributor.author","Boeckel, Göran Ramin"],["dc.contributor.author","Tepasse, Phil-Robin"],["dc.contributor.author","Reitnauer, Lea"],["dc.contributor.author","Koch, Raphael"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Scheithauer, Simone"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Kerkhoff, Andrea"],["dc.contributor.author","Lenz, Georg"],["dc.contributor.author","Krekeler, Carolin"],["dc.contributor.author","Bleckmann, Annalen"],["dc.date.accessioned","2022-08-03T14:40:37Z"],["dc.date.available","2022-08-03T14:40:37Z"],["dc.date.issued","2022-07-31"],["dc.date.updated","2022-08-03T12:15:44Z"],["dc.description.abstract","This study investigated SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated (n = 49) and non-vaccinated (n = 84) cancer patients. A mild course of COVID-19 was documented more frequently in vaccinated cancer patients (49% vs. 29%), while the incidence of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%). In comparison to non-vaccinated patients, admissions to intermediate and intensive care units and the need for non-invasive and invasive respiratory support were reduced by 71% and 50% among vaccinated patients. The median length of hospital stay was 11 days for non-vaccinated and 5 days for vaccinated patients. COVID-19 mortality was reduced by 83% in vaccinated patients. Finally, the median time from SARS-CoV-2 infection to restarting cancer therapy was 12 and 26 days among vaccinated and non-vaccinated groups, respectively. Our results provide evidence for the significant benefits of COVID-19 vaccines for cancer patients.\r\n \r\n \r\n Abstract\r\n COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer patients between the pre- and post-vaccine era. We analyzed SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated and non-vaccinated patients from three German cancer centers. Overall, 133 patients with SARS-CoV-2 were enrolled in pre- and post-vaccine eras: 84 non-vaccinated and 49 vaccinated, respectively. A mild course of COVID-19 was documented more frequently in vaccinated patients (49% vs. 29%), while the frequency of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%, p = 0.023). Particularly, patients with hematologic neoplasms benefited from vaccination in this context (p = 0.031). Admissions to intermediate- and intensive-care units and the necessity of non-invasive and invasive respiratory support were reduced by 71% and 50% among vaccinated patients, respectively. The median length of admission was 11 days for non-vaccinated and 5 days for vaccinated patients (p = 0.002). COVID-19 mortality was reduced by 83% in vaccinated patients (p = 0.046). Finally, the median time from SARS-CoV-2 infection to restarting cancer therapy was 12 and 26 days among vaccinated and non-vaccinated groups, respectively (p = 0.002). Although this study does not have enough power to perform multivariate analyses to account for confounders, it provides data on COVID-19 in non-vaccinated and vaccinated cancer patients and illustrates the potential benefits of COVID-19 vaccines for these patients."],["dc.identifier.doi","10.3390/cancers14153746"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112610"],["dc.language.iso","en"],["dc.relation.eissn","2072-6694"],["dc.rights","CC BY 4.0"],["dc.title","Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","113"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood Cancer Journal"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Flach, Johanna"],["dc.contributor.author","Porret, Naomi"],["dc.contributor.author","Joncourt, Raphael"],["dc.contributor.author","Wiedemann, Gertrud"],["dc.contributor.author","Fiedler, Martin"],["dc.contributor.author","Novak, Urban"],["dc.contributor.author","Amstutz, Ursula"],["dc.contributor.author","Pabst, Thomas"],["dc.date.accessioned","2019-07-09T11:50:49Z"],["dc.date.available","2019-07-09T11:50:49Z"],["dc.date.issued","2018"],["dc.description.abstract","Given the vast phenotypic and genetic heterogeneity of acute and chronic myeloid malignancies, hematologists have eagerly awaited the introduction of next-generation sequencing (NGS) into the routine diagnostic armamentarium to enable a more differentiated disease classification, risk stratification, and improved therapeutic decisions. At present, an increasing number of hematologic laboratories are in the process of integrating NGS procedures into the diagnostic algorithms of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). Inevitably accompanying such developments, physicians and molecular biologists are facing unexpected challenges regarding the interpretation and implementation of molecular genetic results derived from NGS in myeloid malignancies. This article summarizes typical challenges that may arise in the context of NGS-based analyses at diagnosis and during follow-up of myeloid malignancies."],["dc.identifier.doi","10.1038/s41408-018-0148-6"],["dc.identifier.pmid","30420667"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59839"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]